Trial Profile
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 +Dabrafenib Under Adaptable Dosing Schedules in Patients With Advanced Solid Tumors That Are Metastatic or Cannot be Removed by Surgery
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Oct 2014
Price :
$35
*
At a glance
- Drugs Capivasertib (Primary) ; Dabrafenib
- Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Solid tumours
- Focus Adverse reactions
- 11 Aug 2014 New trial record